Bellerophon Therapeutics Liabilities 2024

Bellerophon Therapeutics Aktienanalyse

What does Bellerophon Therapeutics do?

Bellerophon Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of lung diseases. The company was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon's business model is based on the research and development of therapies for the treatment of severe respiratory diseases, particularly pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD). The company works closely with leading researchers and clinicians to develop innovative treatments that can improve the lives of patients with lung diseases. Bellerophon has several divisions aimed at expanding the portfolio of lung diseases. The first division is the development of INOpulse®, a therapy that improves lung function through inhaled nitric oxide (NO). This therapy specializes in the treatment of PH and has already been approved by the FDA in the United States, the European Commission, and other regulatory agencies worldwide. Another division of Bellerophon is the development of treatments using ultra-short-acting beta-agonists (uBAs), which are able to relax the respiratory muscles and improve breathing. This therapy specializes in the treatment of COPD and is based on a novel device designed to improve the effectiveness of uBA therapy. Bellerophon also has several programs in the pipeline for the development of therapies for the treatment of other lung diseases, including pulmonary fibrosis, lung cancer, and cystic fibrosis. These programs are still in the research phase but have the potential to bring forth new innovations in the future. Some of Bellerophon's products include INOpulse®, an inhaled nitric oxide treatment for PH, and the novel device that improves the effectiveness of uBA therapy for COPD. Additionally, the company is working on further product developments in the field of lung diseases. Overall, Bellerophon Therapeutics Inc has already made significant progress in the development of innovative therapies to improve lung function, particularly in the treatment of PH and COPD. With a strong pipeline of products and programs focused on exploring new therapies for the treatment of lung diseases, the company will continue to expand its position in the field of lung diseases and improve the lives of patients with severe respiratory diseases. Bellerophon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Bellerophon Therapeutics's Liabilities

Bellerophon Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bellerophon Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Bellerophon Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Bellerophon Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Bellerophon Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Bellerophon Therapeutics Stock

What is the level of liabilities of Bellerophon Therapeutics this year?

Bellerophon Therapeutics has a debt balance of 5.4 M USD this year.

What were the liabilities of Bellerophon Therapeutics compared to the previous year?

The liabilities of Bellerophon Therapeutics have increased by 2.76% increased compared to the previous year.

What are the consequences of high debt for investors of Bellerophon Therapeutics?

High liabilities can pose a risk for investors of Bellerophon Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Bellerophon Therapeutics?

Low liabilities mean that Bellerophon Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Bellerophon Therapeutics affect the company?

An increase in liabilities of Bellerophon Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Bellerophon Therapeutics affect the company?

A decrease in the liabilities of Bellerophon Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Bellerophon Therapeutics?

Some factors that can influence the liabilities of Bellerophon Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Bellerophon Therapeutics so important for investors?

The liabilities of Bellerophon Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Bellerophon Therapeutics take to modify the liabilities?

To change its liabilities, Bellerophon Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Bellerophon Therapeutics pay?

Over the past 12 months, Bellerophon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bellerophon Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bellerophon Therapeutics?

The current dividend yield of Bellerophon Therapeutics is .

When does Bellerophon Therapeutics pay dividends?

Bellerophon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bellerophon Therapeutics?

Bellerophon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bellerophon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bellerophon Therapeutics located?

Bellerophon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bellerophon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bellerophon Therapeutics from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Bellerophon Therapeutics pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Bellerophon Therapeutics in the year 2023?

In the year 2023, Bellerophon Therapeutics distributed 0 USD as dividends.

In which currency does Bellerophon Therapeutics pay out the dividend?

The dividends of Bellerophon Therapeutics are distributed in USD.